BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
A phase 3 trial of Atezolizumab, Carboplatin, Etoposide in small-cell lung cancer, run by SystImmune Inc., now recruiting.
Overview
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) is a phase 3 interventional study registered as NCT07625644 by SystImmune Inc., with 550 participants planned, started 2026-08-04 and due to reach its primary completion in 2030-01. Interventions recorded: BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin. Conditions listed: Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St
Shares Lurbinectedin, Etoposide, Atezolizumab, Carboplatin.
- TrialA Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Shares Lurbinectedin, Etoposide, Atezolizumab, Carboplatin.
- TrialDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialA Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Shares SystImmune / Sichuan Biokin, Atezolizumab, Small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa
Shares Etoposide, SystImmune / Sichuan Biokin, Carboplatin, Small-cell lung cancer.
- TrialA Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.
- TrialPembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Shares Etoposide, Atezolizumab, Carboplatin, Small-cell lung cancer.